Effect of Fiblaferon-L on the human immune system.
The effect of a new commercial interferon (Fiblaferon L) on the human immune system was studied. Different experiments were performed on human peripheral blood in vitro, in order to observe: (a) the phagocytic capacity of polymorphonuclear leukocytes (PMNL) and monocytes; (b) monocyte adherence index, and (c) percentage of antibody-dependent cellular cytotoxicity (ADCC) against chicken red blood cells (CRBC). Fiblaferon L enhanced all these functions.
D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects*; D002448:Cell Adhesion / Q000187:drug effects; D002645:Chickens; D004912:Erythrocytes / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007158:Immunologic Techniques; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000276:immunology / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects*
D007370:Interferon Type I